



Rule Category:
Medical

Ref: No:
2013-MN-0017

Version Control:
Version No.2.0

Effective Date:
08-02-2019

Revision Date:
February 2020



Bone Mineral Density Studies

Adjudication Guideline

Table of content

Abstract Page 1	Scope Page 2	Adjudication Policy Page 2	Denial codes Page 3	Appendices Page 3
---------------------------	------------------------	--------------------------------------	-------------------------------	-----------------------------

Abstract

For Members

Bone mineral density (BMD) scans are used to assess the mass and bulk of bones. It is measured by a procedure called densitometry (absorptiometry) to determine bone solidity and strength.

Bone density means how much of the bone mass is there in a certain amount of space. The denser the tissues, the less X-rays passes through. In general, the more dense the bone, the stronger it is, and the less likely it is to break. Bone mineral density study is indicated when there is increased tendency to bone fractures.

Daman covers bone mineral density studies, if medically necessary as per best international practice standards and as per policy terms and conditions of each plan administered by Daman.

For Medical Professionals

Bone mineral density study (BMD), also called bone density is a medical term normally referring to the amount of mineral matter per square centimetre of bones. It is measured by a procedure called densitometry. The measurement is painless and non-invasive and involves low radiation exposure. Measurements are most commonly made over the lumbar spine and over the upper part of the hip. The forearm may be scanned if the hip and lumbar spines are not accessible.

Daman covers bone mineral density study for:

1. As screening test for osteoporosis once every 5 years for adults over 50 years of age, and for adults over 18 years and below 50 years of age with high risk of bone fractures, as per policy schedule of benefits.
2. According to medical necessities which are further mentioned on this AR, as per international best practice standards and as per policy terms and conditions of each health insurance plan administered by Daman.

Approved by:
Daman

Responsible:
Medical Standards & Research

Related Adjudication Guidelines:
None

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

INTERNAL

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/350	Version No.:	1	Revision No.:	0	Date of Issue:	13.10.2016	Page No(s).:	1 of 3
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------

Scope

This adjudication rule specifies the coverage details for screening and medically necessary indications of bone mineral density studies as per the policy terms and conditions of each health insurance plan administered by Daman.

Adjudication Policy

Eligibility / Coverage Criteria

Daman covers Bone mineral density (BMD) study for Screening of Osteoporosis as per policy schedule of benefits, only once every 5 years for men and women > 50 years of age.

Adults > 18 years of age with high risk of bone fractures from any of the following conditions:

- History of insufficiency/ fragility fractures.
- Low body mass (less than 127 lbs or 57.6 kg).
- Loss of height, thoracic kyphosis.
- Individuals receiving glucocorticoid or anticonvulsant drugs therapy for more than 3 months.
- Individuals with medical conditions that could alter BMD (e.g. Multiple Myeloma, Organ transplantation).
- Individuals with vertebral abnormalities indicative of osteoporosis, osteopenia, or vertebral fracture.
- Individuals being monitored to assess the response or efficacy of an approved osteoporosis drug therapy (only DEXA scan is considered here).
- Women on long-term (i.e., longer than 2 years) Depo-Provera Contraceptive Injection (CI) therapy (only for plans having contraceptive coverage benefit).
- Hyperthyroidism.
- Osteopenia/ Osteomalacia.
- Patients with high risk diseases that may contribute to lowering the bone density and lead to fractures (e.g. Androgen deprivation therapy for prostate/ breast cancer, Hypogonadism, Primary hyperparathyroidism, Malabsorption syndrome, Cushing's disease).

Below given are the established studies for bone mineral density measurements:

- Dual energy X-ray absorptiometry (DEXA or DXA).
- Quantitative computed tomography (QCT).
- Radiographic absorptiometry (photodensitometry).
- Ultrasound bone mineral density studies.

Daman covers only one of the bone studies, mentioned above for screening/diagnosis of decreased bone mass.

Requirements for Coverage

- ICD and CPT codes must be coded to the highest level of specificity.
- All the BMD studies do not require authorization except for BMD done with CT scans; as all CT scans require authorization including BMD done by CT scan for all Enhanced Plans (except Mubadala plan) and for Thiqa in private providers.

Non-Coverage

- Daman does not cover any of the indications other than listed above for bone mineral density studies.
- Daman considers any of the studies other than listed above as experimental/ unproven, hence not covered.
- Daman does not cover BMD studies for visitor's plan.

INTERNAL

Payment and Coding Rules

Please apply DOH payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

Denial codes

Code description
Service is not clinically indicated based on good clinical practice
Service is not clinically indicated based on good clinical practice, without additional supporting diagnosis/act
Prior approval is required and was not obtained
Service(s) is(are) not covered
Diagnosis (es) is (are) not covered.

Appendices

A. References

- Department of health – Abu Dhabi. UAE
- American College of Rheumatology
- American Academy of Orthopaedic Surgeons
- The international society for clinical densitometry
- The National Osteoporosis Society – UK

B. Revision History

Date	Change(s)
01-11-2013	Release of V1.0
15-07-2014	Release of V1.1 - Disclaimer updated as per system requirements
09-01-2019	Release of V2.0 - Content update

INTERNAL

National Health Insurance Company – Daman (PJSC) (P.O. Box 128888, Abu Dhabi, U.A.E. Tel No. +97126149555 Fax No. +97126149550)

Doc Ctrl No.:	TEMP/350	Version No.:	1	Revision No.:	0	Date of Issue:	13.10.2016	Page No(s).:	3 of 3
---------------	----------	--------------	---	---------------	---	----------------	------------	--------------	--------